TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06173206

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP (Macleods Pharmaceuticals Ltd)
Description: Children who weigh \<10kg will receive Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets; children who weigh \>10kg will receive 500mg sulfadoxine plus 25mg pyrimethamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPAQ (Guilin Pharmaceuticals)
Description: Children will receive 500mg sulfadoxine plus 25mg pyrimethamine as one tablet, and 153mg amodiaquine (as hydrochloride) as one tablet on Day 0, and Children will 153mg amodiaquine (as hydrochloride) as one tablet on days 1 and 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AS (Guilin Pharmaceuticals)
Description: Children will receive 4 mg/kg/day for 7 days
Study: NCT05703061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10-hour Time in Bed
Description: Participants will be asked to increase their time in bed to 10-hours per night for 7 consecutive days.
Study: NCT04564625

Intervention type: OTHER
Intervention: Vitamin D Assessment
Description: index admission vitamin D assessment
Study: NCT05457829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride Liposome+Irinotecan
Description: Q3W, 2 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide+Irinotecan+Vincristine
Description: Q3W, 2 cycles.
Study: NCT06642350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-body electrostimulation
Description: 10 weeks of WB-EMS 1.5x 20 min/week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Training Therapy
Description: 10 weeks of MTT 2x 45 min/week
Study: NCT05086627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Patients were treated with Tislelizumab on the first day of each cycle of CapeOX (Capecitabine+Oxaliplatin).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Short-course radiotherapy
Description: Patients were treated with short-course neoadjuvant radiotherapy
Study: NCT05658809

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thyroidectomy
Description: Patients will be divided into 2 groups group will be treated with total thyroidectomy and the other group will be treated with hemithyroidectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thyroidectomy
Description: Patients will be divided into 2 groups group will be treated with total thyroidectomy and the other group will be treated with hemithyroidectomy
Study: NCT05350709

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mirror therapy
Description: 15 patients will be recruited to each group. Patients will receive a total of 20 sessions of treatment, 5 days a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mirror therapy
Description: 15 patients will be recruited to each group. Patients will receive a total of 20 sessions of treatment, 5 days a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mirror therapy
Description: 15 patients will be recruited to each group. Patients will receive a total of 20 sessions of treatment, 5 days a week.
Study: NCT05147376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin mouthwash
Description: Rinse with 10 ml for 1 minute, twice a day for 28 days after brushing in the morning and at night, following proper oral hygiene and avoid taking any liquid or food for 30 minutes after rinsing.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo mouthwash
Description: Rinse with 10 ml for 1 minute, twice a day for 28 days after brushing in the morning and at night, following proper oral hygiene and avoid taking any liquid or food for 30 minutes after rinsing.
Study: NCT05882812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sustained Acoustic Device with 2.5% Diclofenac Patch
Description: Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm\^2 with 2.5% Diclofenac patches.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sustained Acoustic Device with 0% Diclofenac Patch
Description: Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours with 0% diclofenac patches.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2.5% Diclofenac Patches
Description: Topical pain relief-gel worn for 4 hours at least 5 days a week via SAM patch.
Study: NCT06095219

Intervention type: OTHER
Intervention: Non- contrast Magnetic Resonance Imaging (MRI) of the hip
Description: Asymptomatic volunteers will undergo a non-contrast MRI of the hip at 3 Tesla. Following this, MRI images will be automatically segmented utilizing a validated artificial intelligence based algorithm to calculate 3D outcome parameters.

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI) of the hip with intra-articular contrast agent
Description: The data was derived from a retrospective study involving patients at Inselspital's outpatient clinic who underwent 3 Tesla hip MRI scans with intra-articular contrast agent. A validated artificial intelligence based algorithm was utilized for automated segmentation and the calculation of 3D outcome parameters.

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI) of the hip with intra-articular contrast agent
Description: The data was derived from a retrospective study involving patients at Inselspital's outpatient clinic who underwent 3 Tesla hip MRI scans with intra-articular contrast agent. A validated artificial intelligence based algorithm was utilized for automated segmentation and the calculation of 3D outcome parameters.

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI) of the hip with intra-articular contrast agent
Description: The data was derived from a retrospective study involving patients at Inselspital's outpatient clinic who underwent 3 Tesla hip MRI scans with intra-articular contrast agent. A validated artificial intelligence based algorithm was utilized for automated segmentation and the calculation of 3D outcome parameters.

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI) of the hip with intra-articular contrast agent
Description: The data was derived from a retrospective study involving patients at Inselspital's outpatient clinic who underwent 3 Tesla hip MRI scans with intra-articular contrast agent. A validated artificial intelligence based algorithm was utilized for automated segmentation and the calculation of 3D outcome parameters.

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI) of the hip with intra-articular contrast agent
Description: The data was derived from a retrospective study involving patients at Inselspital's outpatient clinic who underwent 3 Tesla hip MRI scans with intra-articular contrast agent. A validated artificial intelligence based algorithm was utilized for automated segmentation and the calculation of 3D outcome parameters.
Study: NCT04564625

Intervention type: OTHER
Intervention: Fracture
Description: rate of nonunion (i.e., failure of a fractured bone to heal)
Study: NCT05817396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion of Physical Activity-related Health Competence (PAHCO)
Description: Intervention for the curriculum content PAHCO at nursing schools in Bavaria

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion of Physical Activity-related Health Competence (PAHCO)
Description: Intervention for the curriculum content PAHCO at nursing schools in Bavaria

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion of Physical Activity-related Health Competence (PAHCO)
Description: Intervention for the curriculum content PAHCO at nursing schools in Bavaria
Study: NCT05086627

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy
Description: Patients were treated with short-course neoadjuvant radiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine+Oxaliplatin
Description: Patients were treated with neoadjuvant chemotherapy with CapeOX (Capecitabine+Oxaliplatin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine+Oxaliplatin
Description: Patients were treated with neoadjuvant chemotherapy with CapeOX (Capecitabine+Oxaliplatin).
Study: NCT05431062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: %0.25

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: %0.25

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: %0.25
Study: NCT05444452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implanatation of Genoss DES sirolimus-eluting coronary system
Description: Percutaneous coronary intervention will proceed as per clinical guidelines, under operator's discretion. Genoss stent will be implanted if the lesion is deemed necessary to be revascularized by stenting

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implanatation of Xience DES everolimus-eluting coronary system
Description: Percutaneous coronary intervention will proceed as per clinical guidelines, under operator's discretion. Xience stent will be implanted if the lesion is deemed necessary to be revascularized by stenting
Study: NCT04733963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib Plus Capecitabine
Description: Maintenance therapy with fruquintinib at the dose determined in phase safety lead-in, orally once daily, on d1-21, given every 4 weeks (Q4W); plus capecitabine at the dose 850mg/m2, orally twice daily, d1-7, given every 2 weeks (Q2W); until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab Plus Capecitabine
Description: Maintenance therapy with bevacizumab at the dose 5mg/kg q2w (Q2W); plus capecitabine at the dose 850mg/m2, orally twice daily, d1-7, given every 2 weeks (Q2W); until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
Study: NCT06163066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Newborn Basic Care Training
Description: These talented fathers will be given both face-to-face practical training and the industrial web-based training type of information technologies will be used. In this way, the positive developments provided by the two trainings will be abandoned and the understandability and usefulness of the training from the people's perspective will be increased. A website suitable for mobile phones will be designed by transferring digital materials. With this website, fathers will be able to access information about basic care via phone whenever and wherever they want. Thus, in a short time, without human resources and time, all the fathers in need throughout the country will reach the capacity to obtain appropriate information.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Newborn Basic Care Training
Description: These talented fathers will be given both face-to-face practical training and the industrial web-based training type of information technologies will be used. In this way, the positive developments provided by the two trainings will be abandoned and the understandability and usefulness of the training from the people's perspective will be increased. A website suitable for mobile phones will be designed by transferring digital materials. With this website, fathers will be able to access information about basic care via phone whenever and wherever they want. Thus, in a short time, without human resources and time, all the fathers in need throughout the country will reach the capacity to obtain appropriate information.
Study: NCT06207383

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conduction system pacing
Description: Conduction system pacing (either His bundle pacing or left bundle branch area pacing)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atrioventricular nodal ablation
Description: Catheter ablation of the atrioventricular node
Study: NCT03086655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tel-me-box with reminder features
Description: Participants will meet with a study staff member to go over their daily routines, including their pill taking schedule, and to work out a plan for tailored reminders. The participant will choose from the reminders available and convey their preferences regarding when reminders should be sent for the TMB. Preferences will be stored in an online secure database. If requested by the participant, the reminder schedule and type of reminder can be reprogrammed by study staff via an online portal. When the reminder is reprogrammed the TMB receives a new configuration SMS to update the device reminder settings.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tel-me-box
Description: Participants receive tel-me-box device with no reminder features added.
Study: NCT06582680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambient Heat
Description: Subjects will spend 3-hours in a heat chamber at 41°C and 40% humidity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambient Heat
Description: Subjects will spend 3-hours in a heat chamber at 41°C and 40% humidity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambient Heat
Description: Subjects will spend 3-hours in a heat chamber at 41°C and 40% humidity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambient Heat
Description: Subjects will spend 3-hours in a heat chamber at 41°C and 40% humidity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambient Heat
Description: Subjects will spend 3-hours in a heat chamber at 41°C and 40% humidity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambient Heat
Description: Subjects will spend 3-hours in a heat chamber at 41°C and 40% humidity.
Study: NCT06207383

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Atrial fibrillation ablation
Description: Catheter ablation of atrial fibrillation with pulmonary vein isolation (using technique of operator's choice, with additional lesions if deemed necessary)
Study: NCT05746585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Talk Web-based resources
Description: Educational videos and podcasts for parents and their sons
Study: NCT05163678

Intervention type: OTHER
Intervention: monitoring naturalistic of cohort
Description: Assessment at the start of care in the Relais (T0), at the end (T1) and 6 months later (T6).
Study: NCT05890781

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Skin biopsy
Description: Skin biopsy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fresh tumor sample
Description: Fresh tumor sample

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample
Description: Blood sample in heparin tubes (highly recommended), to be collected before starting treatment or as soon as hematological recovery has been reached

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Healthy tissue from the tumor
Description: Healthy tissue from the tumor site whenever possible
Study: NCT05158972

Intervention type: DRUG
Intervention: Dymista
Description: 1 spray per nostril twice daily up to four weeks
Study: NCT05890781

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Spinal cerebrospinal fluid (SCF)
Description: Spinal cerebrospinal fluid (SCF) whenever possible
Study: NCT06357065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active transport educational program based on the ecological model
Description: The intervention is structured according to the following units: Unit I: benefits of physical activity on health and healthy habits in schoolchildren; Unit II: Active Transportation: Experiences from other countries; Unit III: Analysis of the environmental characteristics of the school environment of each establishment; and Unit VI: Road safety for pedestrians and cyclists. This last topic will be broken down considering analysis and prevention of accidents with automobiles, pedestrian regulations, signaling, and cyclist safety. The sessions of the last month of intervention (November) will include practical walking activities in the school environment (outside the school). Depending on the possibilities of each school, cycling sessions will be included.
Study: NCT05938413

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wise App with medication adherence reminders
Description: The Intervention group will receive the Wise App that delivers medication adherence reminders.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHW Sessions
Description: The Intervention group will complete sessions with a community health worker (CHW).
Study: NCT06257459

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subinguinal varicocelectomy
Description: exision or preservation of spermatic cord lipoma during subinguinal varicocelectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subinguinal varicocelectomy
Description: exision or preservation of spermatic cord lipoma during subinguinal varicocelectomy
Study: NCT06181019

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 mg of mirabegron
Description: Patients in the control group were treated with 50 mg of mirabegron (Astellas Pharma, Tokyo, Japan) for 12 weeks.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: acupuncture combined with mirabegron.
Description: Patients in the treatment group were treated with acupuncture combined with mirabegron.
Study: NCT05744505

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1565nm Non-ablative Fractional Laser
Description: Every 3 weeks

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Every 3 weeks
Study: NCT05107921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromfenac Sodium
Description: The study participants will receive bromfenac sodium hydrate eyedrops twice daily for 14 days.
Study: NCT05670600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: foot and ankle exercise
Description: Foot and Ankle Exercise Phase~1. Pulling the foot upwards from the ankle~2. Bending the foot down from the ankle~3. Spreading the feet like a fan, moving the toes in and out to the right and left~4. Circle drawing exercise with ankle~5. Towel folding exercise~6. Bottle rolling exercise under the feet (The water in the bottle will be warm tap water)
Study: NCT05069129

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)
Description: Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08) in the deltoid muscle of the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)
Description: Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08) in the deltoid muscle of the upper arm
Study: NCT06072274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The virtual reality educational modules
Description: The experimental group will participate in a dementia education program combining VR lasting approximately 2-3 hours. The virtual reality educational modules predominantly offer first-person narratives that delineate various symptoms associated with dementia.
Study: NCT05186467

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intraperitoneal Magnesium sulfate
Description: Intraperitoneal (IP) group will receive 100 ml normal saline infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline intraoperatively then intraperitoneal wash of 100 ml normal saline containing 30 mg/kg MgSO4 at the end of laparoscopy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous magnesium sulfate
Description: Intravenous (IV) group will receive 100 ml normal saline containing MgSO4 30 mg/kg infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline containing MgSO4 (8mg/kg) intraoperatively then intraperitoneal wash using 100 ml normal saline at the end of laparoscopy.
Study: NCT05690295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolonged resistance-type exercise training
Description: All volunteers will be subjected to 12 weeks of whole-body resistance-type exercise training (3x/wk).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolonged resistance-type exercise training
Description: All volunteers will be subjected to 12 weeks of whole-body resistance-type exercise training (3x/wk).
Study: NCT06042088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular Size Glove and Bigger One
Description: Different sizes of surgical gloves will be worn by participants

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular Size Glove and Bigger One
Description: Different sizes of surgical gloves will be worn by participants

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular Size Glove and Bigger One
Description: Different sizes of surgical gloves will be worn by participants
Study: NCT06538623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome Irinotecan Injection II combined with Oxaliplatin, Fluorouracil, Leucovorin
Description: Liposome Irinotecan: 60 mg/m², Oxaliplatin: 85 mg/m², Fluorouracil: 2400 mg/m², Leucovorin: 400 mg/m², every 3 weeks (Q3W), administered via hepatic arterial infusion (HAIC);

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegodor
Description: Tegodor: 40 mg per dose, twice daily for seven days, every 3 weeks (Q3W), taken orally.
Study: NCT05550012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low-dose CT
Description: those patients undergo low-dose liver CT in portal vein and delayed phase.
Study: NCT05676892

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Description: Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and a 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle, and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed, and the skin was sutured

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Description: Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and a 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle, and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed, and the skin was sutured